VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+8.21%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$214M
AUM Growth
+$9.71M
(+4.8%)
Cap. Flow
+$1.5M
Cap. Flow
% of AUM
0.7%
Top 10 Holdings %
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36
Top Buys
| 1 |
OCCI
OFS Credit Co
OCCI
|
$2.06M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
$1.96M |
| 3 |
Applovin
APP
|
$1.49M |
| 4 |
Constellation Energy
CEG
|
$1.32M |
| 5 |
ECC
Eagle Point Credit Co
ECC
|
$1.26M |
Top Sells
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$1.49M |
| 2 |
Gen Digital
GEN
|
$1.01M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$1M |
| 4 |
Adobe
ADBE
|
$989K |
| 5 |
Steris
STE
|
$907K |
Sector Composition
| 1 | Financials | 28.16% |
| 2 | Healthcare | 18.37% |
| 3 | Technology | 14.33% |
| 4 | Industrials | 8.16% |
| 5 | Consumer Discretionary | 6.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
401
Bicycle Therapeutics
BCYC
$483M
| $85.7K | 0.04% |
3,789
+64
| +2% | +$1.45K |
|
402
Syndax Pharmaceuticals
SNDX
$1.39B
| $85.7K | 0.04% |
4,451
+78
| +2% | +$1.5K |
|
|
SLN
403
Silence Therapeutics
SLN
$247M
| $85K | 0.04% |
4,674
+83
| +2% | +$1.51K |
|
404
Tango Therapeutics
TNGX
$760M
| $84.6K | 0.04% |
10,984
+194
| +2% | +$1.49K |
|
405
Immunome
IMNM
$853M
| $84K | 0.04% |
5,743
+99
| +2% | +$1.45K |
|
406
Spyre Therapeutics
SYRE
$1.03B
| $83.8K | 0.04% |
2,848
+51
| +2% | +$1.5K |
|
|
CMPS
407
Compass Pathways
CMPS
$489M
| $83.7K | 0.04% |
13,281
+237
| +2% | +$1.49K |
|
408
Kura Oncology
KURA
$706M
| $83.5K | 0.04% |
4,275
+78
| +2% | +$1.52K |
|
409
Relay Therapeutics
RLAY
$690M
| $83.4K | 0.04% |
11,781
+212
| +2% | +$1.5K |
|
410
Arcus Biosciences
RCUS
$1.23B
| $82.9K | 0.04% |
5,424
+99
| +2% | +$1.51K |
|
411
Immatics
IMTX
$695M
| $81.2K | 0.04% |
7,115
+125
| +2% | +$1.43K |
|
412
Merus
MRUS
$5.01B
| $79.7K | 0.04% |
1,595
+25
| +2% | +$1.25K |
|
|
VERV
413
DELISTED
Verve Therapeutics
VERV
| $79.6K | 0.04% |
16,455
+290
| +2% | +$1.4K |
|
414
NewAmsterdam Pharma
NAMS
$2.89B
| $78.7K | 0.04% |
4,738
+81
| +2% | +$1.35K |
|
415
Structure Therapeutics
GPCR
$1.14B
| $78.4K | 0.04% |
1,787
+34
| +2% | +$1.49K |
|
416
Scholar Rock
SRRK
$3.12B
| $78.3K | 0.04% |
9,771
+171
| +2% | +$1.37K |
|
417
IDEAYA Biosciences
IDYA
$2.26B
| $75.1K | 0.04% |
2,369
+44
| +2% | +$1.39K |
|
418
Rocket Pharmaceuticals
RCKT
$349M
| $74.4K | 0.03% |
4,028
+68
| +2% | +$1.26K |
|
419
Regenxbio
RGNX
$498M
| $73.9K | 0.03% |
7,043
+122
| +2% | +$1.28K |
|
|
AUTL
420
Autolus Therapeutics
AUTL
$386M
| $73.9K | 0.03% |
20,348
+364
| +2% | +$1.32K |
|
421
89bio
ETNB
$1.28B
| $73.4K | 0.03% |
9,923
+179
| +2% | +$1.33K |
|
422
Intellia Therapeutics
NTLA
$1.25B
| $73K | 0.03% |
3,550
+63
| +2% | +$1.3K |
|
423
Prothena Corp
PRTA
$442M
| $72.2K | 0.03% |
4,315
+79
| +2% | +$1.32K |
|
424
AbCellera Biologics
ABCL
$1.24B
| $72K | 0.03% |
27,678
+493
| +2% | +$1.28K |
|
425
Cullinan Oncology
CGEM
$408M
| $70.8K | 0.03% |
4,228
+75
| +2% | +$1.26K |
|